SAN FRANCISCO – 2013 was not the best PR year for biopharmaceutical companies in Asia. The vast potential for success by doing business in those markets is complicated after a frenzied growth mode and now executives are faced with challenges of managing those businesses since bribery and corruption scandals have rocked Glaxosmithkline plc.